Table of Contents List of Tables List of Figures Introduction Global Markets Direct Report Coverage Insulin Like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1) - Overview Insulin Like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1) - Therapeutics Development Products under Development by Stage of Development Products under Development by Therapy Area Products under Development by Indication Products under Development by Companies Products under Development by Universities/Institutes Insulin Like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1) - Therapeutics Assessment Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Insulin Like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1) - Companies Involved in Therapeutics Development Boehringer Ingelheim GmbH Genervon Biopharmaceuticals LLC Regulaxis SAS Insulin Like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1) - Drug Profiles CIGB-845 - Drug Profile Product Description Mechanism Of Action R&D Progress GM-6 - Drug Profile Product Description Mechanism Of Action R&D Progress M-610.27 - Drug Profile Product Description Mechanism Of Action R&D Progress M-630 - Drug Profile Product Description Mechanism Of Action R&D Progress M-7085 - Drug Profile Product Description Mechanism Of Action R&D Progress Recombinant Protein to Inhibit IGF-1 and IGF-2 for Breast Cancer - Drug Profile Product Description Mechanism Of Action R&D Progress Synthetic Peptides to Inhibit IGF1 for Oncology - Drug Profile Product Description Mechanism Of Action R&D Progress xentuzumab - Drug Profile Product Description Mechanism Of Action R&D Progress Insulin Like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1) - Dormant Products Insulin Like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1) - Discontinued Products Insulin Like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1) - Product Development Milestones Featured News & Press Releases Dec 08, 2017: GM604 Is a Multi-Target Regulator That Provides a Novel Treatment Strategy for ALS Mar 23, 2017: Confidential Data from Genervon ALS Phase 2A Clinical Trial Were Released and Published Jan 10, 2017: Genervon Releases ALS, PD and AD Disease­ Associated Gene Lists Modulated by GM6 and Encourages Researchers to Explore New Discoveries beyond Single Target Drug Development Paradigm Dec 27, 2016: ALS and Alzheimer's disease bioinformatics reports confirm GM6's role as regulator of disease-relevant pathways Jun 06, 2016: GENERVON GM604 received EUs orphan drug designation to treat ALS May 23, 2016: ALS Patients from Around the World Responding Well to Genervons GM604 May 03, 2016: GM604 to Be Granted “Orphan Drug” Status in Europe Sep 22, 2015: Genervon GM604 Reduced TDP-43 Protein Aggregates and Slowed Down ALS Progression Jun 29, 2015: Genervon Filed Patent for Using GM604 Modulations of ALS Disease Biomarkers Showing Homeostasis, Leading to Prognosis and Therapeutic Treatment for ALS Disease Apr 17, 2015: Amyotrophic Lateral Sclerosis Statement; FDA Jan 08, 2015: Genervon Announces ALS Compassionate Use Results Oct 19, 2014: Genervon Announces ALS and PD Phase 2a Trial Results Jun 30, 2014: Genervon Announces Biomarker Data from GALS-001 Clinical Trial for ALS Apr 28, 2014: Genervon Successfully Completes its Phase 2a Clinical Trial for ALS Mar 03, 2014: FDA Grants “Orphan Drug” Designation for Genervon’s Breakthrough Multi-Target ALS Bio-Drug GM604 Appendix Methodology Coverage Secondary Research Primary Research Expert Panel Validation Contact Us Disclaimer

List of Tables Number of Products under Development by Stage of Development, H1 2018 Number of Products under Development by Therapy Areas, H1 2018 Number of Products under Development by Indication, H1 2018 Number of Products under Development by Companies, H1 2018 Products under Development by Companies, H1 2018 Number of Products under Investigation by Universities/Institutes, H1 2018 Products under Investigation by Universities/Institutes, H1 2018 Number of Products by Stage and Mechanism of Actions, H1 2018 Number of Products by Stage and Route of Administration, H1 2018 Number of Products by Stage and Molecule Type, H1 2018 Pipeline by Boehringer Ingelheim GmbH, H1 2018 Pipeline by Genervon Biopharmaceuticals LLC, H1 2018 Pipeline by Regulaxis SAS, H1 2018 Dormant Products, H1 2018 Dormant Products, H1 2018 (Contd..1), H1 2018 Discontinued Products, H1 2018 List of Figures Number of Products under Development by Stage of Development, H1 2018 Number of Products under Development by Therapy Areas, H1 2018 Number of Products under Development by Top 10 Indications, H1 2018 Number of Products by Mechanism of Actions, H1 2018 Number of Products by Stage and Mechanism of Actions, H1 2018 Number of Products by Routes of Administration, H1 2018 Number of Products by Stage and Routes of Administration, H1 2018 Number of Products by Molecule Types, H1 2018 Number of Products by Stage and Molecule Types, H1 2018

Boehringer Ingelheim GmbH Genervon Biopharmaceuticals LLC Regulaxis SAS